Dianthus Therapeutics (DNTH) Expected to Announce Quarterly Earnings on Thursday

Dianthus Therapeutics (NASDAQ:DNTH) is projected to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.69) per share and revenue of $0.86 million for the quarter.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.40 million. On average, analysts expect Dianthus Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Dianthus Therapeutics Price Performance

Dianthus Therapeutics stock opened at $20.74 on Wednesday. The stock’s fifty day moving average price is $22.34 and its two-hundred day moving average price is $24.70. Dianthus Therapeutics has a one year low of $18.13 and a one year high of $33.77. The firm has a market cap of $613.84 million, a PE ratio of -8.30 and a beta of 1.82.

Analysts Set New Price Targets

DNTH has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Wedbush reaffirmed an “outperform” rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Guggenheim reaffirmed a “buy” rating and issued a $84.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Finally, TD Cowen began coverage on Dianthus Therapeutics in a report on Friday, December 20th. They issued a “buy” rating on the stock. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $52.14.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.